{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:55:22Z","timestamp":1781758522742,"version":"3.54.5"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>For B-cell acute lymphoblastic leukemia (B-ALL), the dominance of traditional chemotherapy is being rewritten, with multiple promising novel treatment approaches continually emerging. Immunotherapy (blinatumomab, Blina or inotuzumab ozogamicin, InO) has demonstrated efficacy in the induction phase for elderly patients newly diagnosed with B-ALL, but its role in newly diagnosed patients fit for intensive chemotherapy is being explored. This study aims to evaluate the efficacy and safety of immunotherapy with or without low-intensity chemotherapy in fit patients newly diagnosed with B-ALL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>We retrospectively enrolled 133 patients with newly diagnosed B-ALL who met the inclusion criteria at Qilu Hospital of Shandong University. Patients were divided into two groups based on whether Blina\/InO was used in the first-line induction therapy regimen. The immunotherapy group (IG) consisted of 25 patients, while the chemotherapy group (CG) consisted of 108 patients. Propensity score matching (PSM) was performed to match the IG and CG patients in a 1:1 ratio based on age, sex, risk stratification, comorbidities and Philadelphia chromosome status. After matching, there were 25 patients in each group. Primary research objectives included remission rates and minimal residual disease (MRD) negativity rate. Secondary objectives included adverse events. Data management and statistical analysis were performed using SPSS and R software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The IG achieved a higher MRD negativity rate (88% vs. 48%,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.002). Compared with the CG, the IG had a higher median minimum of neutrophil count (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001) and a higher median minimum of platelet count (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.001). Furthermore, the duration of neutrophil count &amp;lt; 0.5\u202f\u00d7\u202f10\n                      <jats:sup>9<\/jats:sup>\n                      \/L (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.033), hemoglobin level &amp;lt; 80\u202fg\/L (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.038) and platelet count &amp;lt; 30\u202f\u00d7\u202f10\n                      <jats:sup>9<\/jats:sup>\n                      \/L (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.006) was shorter in the IG. They also experienced fewer pulmonary infections (44% vs. 84%,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.003). Additionally, the IG required fewer red blood cell transfusions (4 vs. 8 u,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.012) and platelet transfusions (0 vs. 48 u,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In the PSM-based retrospective cohort study, an immunotherapy-based first-line treatment strategy showed promising early treatment responses and tolerability to hematologic toxicity in fit patients newly diagnosed with B-ALL. These exploratory findings provide additional real-world evidence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1843800","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:38:56Z","timestamp":1781757536000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunotherapy with or without low-intensity chemotherapy versus conventional chemotherapy as first-line treatment for newly diagnosed B-ALL patients fit for intensive chemotherapy: a propensity score-matched study"],"prefix":"10.3389","volume":"13","author":[{"given":"Bingqian","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Hematology, Qilu Hospital of Shandong University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Qilu Hospital of Shandong University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Qilu Hospital of Shandong University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Qilu Hospital of Shandong University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixue","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Qilu Hospital of Shandong University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaoyu","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Hematology, Qilu Hospital of Shandong University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Hematology, Qilu Hospital of Shandong University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2147\/blctt.S223894","article-title":"Evaluating Blinatumomab for the treatment of relapsed\/refractory ALL: design, development, and place in therapy","volume":"10","author":"Sigmund","year":"2020","journal-title":"Blood Lymphat Cancer."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/bs9.0000000000000126","article-title":"A typical bedside-to-bench investigation of leukemogenic driver MEF2D fusion reveals new targeted therapy in B-cell acute lymphoblastic leukemia","volume":"4","author":"Zhang","year":"2022","journal-title":"Blood Sci"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e2423169122","DOI":"10.1073\/pnas.2423169122","article-title":"Metabolomic insights into pathogenesis and therapeutic potential in adult acute lymphoblastic leukemia","volume":"122","author":"Wang","year":"2025","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"4623","DOI":"10.3390\/cancers15184623","article-title":"Blinatumomab and InOtuzumab Ozogamicin sequential use for the treatment of relapsed\/refractory acute lymphoblastic leukemia: a real-life campus all study","volume":"15","author":"Fracchiolla","year":"2023","journal-title":"Cancer"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2040620720910023","article-title":"Evaluation and management of measurable residual disease in acute lymphoblastic leukemia","volume":"11","author":"Abou Dalle","year":"2020","journal-title":"Ther Adv Hematol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e959","DOI":"10.1016\/s2352-3026(24)00285-0","article-title":"Frontline treatment of adults with newly diagnosed B-cell acute lymphoblastic leukaemia","volume":"11","author":"Aldoss","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of Postreinduction therapy consolidation with Blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia","volume":"325","author":"Brown","year":"2021","journal-title":"JAMA"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11899-025-00764-z","article-title":"Transforming the treatment of acute lymphoblastic leukemia: the role of bispecific antibodies, antibody-drug conjugates, and CAR T-cell therapy","volume":"20","author":"Najdi","year":"2025","journal-title":"Curr Hematol Malig Rep"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.5045\/br.2021.2021058","article-title":"Induction-related mortality in adolescents and young adults with acute lymphoblastic leukemia in a resource-limited setting: do treatment-related complications create more impact than disease biology?","volume":"57","author":"Vongngakesone","year":"2022","journal-title":"Blood Res"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e533","DOI":"10.1016\/j.clml.2025.03.001","article-title":"Real-world data on outcome of Burkitt lymphoma and Burkitt leukemia treated according to the GMALL B-ALL\/NHL 2002 protocol: a tertiary center experience","volume":"25","author":"Kosch","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1587185","DOI":"10.3389\/fonc.2025.1587185","article-title":"Efficacy and safety of blinatumomab in Chinese patients with relapsed\/refractory B-cell acute lymphoblastic leukemia: a single-center retrospective study","volume":"15","author":"Wang","year":"2025","journal-title":"Front Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1182\/bloodadvances.2022009596","article-title":"Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial","volume":"7","author":"Bassan","year":"2023","journal-title":"Blood Adv"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.3324\/haematol.2018.201053","article-title":"A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia","volume":"104","author":"Bassan","year":"2019","journal-title":"Haematologica"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2147\/blctt.S270134","article-title":"Clinical value of measurable residual disease in acute lymphoblastic leukemia","volume":"12","author":"Hein","year":"2022","journal-title":"Blood Lymphat Cancer"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1743310","DOI":"10.3389\/fonc.2026.1743310","article-title":"Case report: safety analysis of blinatumomab consolidation therapy in two cases of acute B-cell lymphoblastic leukemia in complete remission complicated with immune effector cell-associated neurotoxicity syndrome","volume":"16","author":"Ma","year":"2026","journal-title":"Front Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"071","DOI":"10.1055\/s-0041-1729730","article-title":"Minimal residual disease in AcuteLymphoblastic leukemia","volume":"42","author":"Patil","year":"2021","journal-title":"Ind J Med Paediatr Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1182\/blood.2024027500","article-title":"Up-front blinatumomab improves MRD clearance and outcome in adult Ph- B-lineage ALL: the GIMEMA LAL2317 phase 2 study","volume":"145","author":"Bassan","year":"2025","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e7062","DOI":"10.1002\/cam4.7062","article-title":"Reduced-dose chemotherapy followed by blinatumomab in induction therapy for newly diagnosed B-cell acute lymphoblastic leukemia","volume":"13","author":"Lu","year":"2024","journal-title":"Cancer Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1016\/s2352-3026(22)00319-2","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-Centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e433","DOI":"10.1016\/s2352-3026(23)00073-x","article-title":"Mini-hyper-CVD plus InOtuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.1200\/jco.24.00490","article-title":"InOtuzumab ozogamicin and low-intensity chemotherapy in older patients with newly diagnosed CD22+ Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia","volume":"42","author":"Chevallier","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/s1470-2045(18)30011-1","article-title":"InOtuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study","volume":"19","author":"Kantarjian","year":"2018","journal-title":"Lancet Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3760\/cma.j.cn121090-20240319-00102","article-title":"For hematology oncology committee, Chinese anti-Cancer association and Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association. Chinese guideline for diagnosis and treatment of adult acute lymphoblastic leukemia(2024)","volume":"45","author":"Wang","year":"2024","journal-title":"Chin J Hematol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40364-021-00294-9","article-title":"The landscape of bispecific T cell engager in cancer treatment","volume":"9","author":"Zhou","year":"2021","journal-title":"Biomark Res"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s12672-025-01968-8","article-title":"Reduced-dose chemotherapy followed by blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia: a propensity-matched comparison with hyper-CVAD","volume":"16","author":"Lu","year":"2025","journal-title":"Discov Oncol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1182\/blood-2023-180472","article-title":"Dose reduced chemotherapy in sequence with Blinatumomab for newly diagnosed older patients with Ph\/BCR:ABL negative B-precursor adult lymphoblastic leukemia (ALL): preliminary results of the GMALL bold trial","volume":"142","author":"Goekbuget","year":"2023","journal-title":"Blood"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1843800\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:39:06Z","timestamp":1781757546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1843800\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":26,"alternative-id":["10.3389\/fmed.2026.1843800"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1843800","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"article-number":"1843800"}}